ABBVIE INC. Patent applications |
Patent application number | Title | Published |
20160115225 | Methods of Reducing Methylglyoxal (MGO) Modification of Recombinant Proteins in Cell Culture - Methods are provided for controlling the levels of acidic species when a protein of interest is expressed by host cells. One particular example of an acidic species is methylglyoxal (MGO). Reduction of acidic species such as MGO may be achieved by regulating the glucose consumption of the cell culture or by modulating the cysteine/glutathione metabolic pathways. | 04-28-2016 |
20160082184 | Devices And Methods For Delivering A Beneficial Agent To A User - Drug delivery reservoir for delivery of a beneficial agent to a user includes a drug delivery reservoir housing having a fluid reservoir defined therein. The drug delivery reservoir housing has a drug delivery reservoir base region. The drug delivery reservoir includes a dip tube extending inside the fluid reservoir. The dip tube includes a tubular wall defining a flow lumen. The tubular wall has at least one aperture defined therein and spaced proximally from a distal end of the tubular wall in fluid communication with the fluid reservoir. The drug delivery reservoir includes an adaptor disposed external to the drug delivery reservoir housing and coupled to a proximal end of the dip tube. | 03-24-2016 |
20160075692 | Indazole Ureas and Method of Use - Compounds of formula (I) | 03-17-2016 |
20160074462 | Method of Treating HCV - This application features methods of treating HCV using Compound 1/r, Compound 2 and/or Compound 3. | 03-17-2016 |
20160074368 | VELIPARIB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN SMOKERS - This invention pertains to a method for the treatment of non-small cell lung cancer in a subject who is a smoker, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (veliparib or ABT-888), or a pharmaceutically acceptable salt thereof, in combination with carboplatin and paclitaxel. | 03-17-2016 |
20160074363 | METHODS FOR IMPROVING LIPID PROFILES USING ATRASENTAN - The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol. | 03-17-2016 |
20160060257 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS - Disclosed are compounds of Formula (IIa), | 03-03-2016 |
20160031986 | Therapeutic DLL4 Binding Proteins - DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis. | 02-04-2016 |
20160031880 | Nampt and Rock Inhibitors - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed. | 02-04-2016 |
20150337042 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES - The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs. | 11-26-2015 |
20150322047 | Crystal Forms - The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in one of FIGS. | 11-12-2015 |
20150297596 | ISOXAZOLINES AS THERAPEUTIC AGENTS - The present invention provides compound of Formula (I) | 10-22-2015 |
20150283199 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. | 10-08-2015 |
20150283198 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. | 10-08-2015 |
20150266860 | CRYSTALLINE FORM OF A DRUG - Atrasentan Hydrochloride Crystalline Form 3, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed. | 09-24-2015 |
20150253289 | CHARACTERIZATION AND/OR DETECTION OF STRUCTURAL CHARACTERISTICS ASSOCIATED WITH SYRINGES AND/OR AUTOMATIC INJECTION DEVICES BASED ON ACOUSTICS - Exemplary embodiments relate to characterizing and/or detecting structural characteristics of syringes (e.g., bare syringes or syringes included in automatic injection devices) using acoustic vibrations. Exemplary embodiments can position a transducer proximate to a syringe so that the transducer vibrates at one or more frequencies and a response of the syringe to the vibrations can be received via the receiver. The response of syringe can be processed to determine a structural characteristic of the syringe. | 09-10-2015 |
20150226659 | SYSTEMS AND METHODS FOR DETECTION OF PARTICLES IN A BENEFICIAL AGENT - Detection of particles in a liquid beneficial agent contained within a container includes selectively illuminating at least a portion of the liquid beneficial, obtaining an image from the illuminated portion of the liquid beneficial agent, analyzing image data representing the image, using a data processor, to obtain a particle concentration, measuring an image intensity value of the image data using the data processor, and determining a quality level of the liquid beneficial agent using the data processor based on the particle concentration and the measured image intensity value. | 08-13-2015 |
20150218194 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 08-06-2015 |
20150218165 | TETRACYCLIC CDK9 KINASE INHIBITORS - Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, | 08-06-2015 |
20150210735 | Isolation and Purification of Antibodies Using Protein A Affinity Chromatography - Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably Protein A affinity, ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention. | 07-30-2015 |
20150210708 | NOVEL TRICYCLIC COMPOUNDS - The invention provides a compound of Formula (I) | 07-30-2015 |
20150196615 | Methods for Treating HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 07-16-2015 |
20150191437 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS - This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such compositions. | 07-09-2015 |
20150184648 | PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY - Pump includes a motor and a cam shaft coupled to the motor for rotation about a longitudinal axis of the cam shaft. The cam shaft has at least one radially-outward projection defining a helical engagement portion disposed along a length of the cam shaft. A plurality of finger plates are disposed along the length of the cam shaft, each finger plate mounted for movement in a transverse direction relative to the longitudinal axis of the cam shaft. Each finger plate has an aperture defined therein to receive the cam shaft therethrough. Each aperture has a substantially straight edge region and an opposing edge region. Engagement of the helical engagement portion with the substantially flat edge region during rotation of the cam shaft urges the finger plate transversely toward an extended position. | 07-02-2015 |
20150182698 | PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY - Device for delivering a beneficial agent to a user includes a cassette including a cassette housing with a fluid reservoir defined therein, the cassette housing having a cassette base region, and a delivery tube fluidly coupled with the fluid reservoir. The device also includes a pump having a pump housing containing a pump assembly and further having a receiving region to receive the cassette base region. The pump assembly includes a fluid drive component disposed proximate the receiving region, a main controller circuit board coupled to and configured to control the fluid drive component, and at least one secondary circuit board foldably joined to the main controller circuit board through a flexible substrate and disposed within the interior in a stacked relationship relative the main controller circuit board. | 07-02-2015 |
20150182697 | PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY - Device for delivering a beneficial agent to a user includes a cassette including a cassette housing with a fluid reservoir, the cassette housing having a cassette base region, and a delivery tube. The device also includes a pump having a pump housing containing a pump assembly and having a receiving region to receive the cassette base region. The pump assembly includes a fluid drive component, a display, a plurality of input buttons. The pump assembly also includes a first processor coupled to the fluid drive component and the display and configured to reduce power to the fluid drive component and the display when the pump is in an inactive state, and a second processor coupled to the first processor and the plurality of input buttons, the second processor configured to provide an activation signal to the first processor when one or more of the plurality of input buttons is deployed. | 07-02-2015 |
20150182689 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER - Device for delivering a beneficial agent includes a cassette including a cassette housing with a fluid reservoir and a cassette base region. The device also includes a delivery tube. The device also includes a pump including a pump housing containing a pump assembly having a fluid drive component. The pump housing has a receiving region to receive the cassette base region. The fluid drive component is proximate the receiving region. A lock member is coupled to the pump housing and movable between an open position and a closed position. The cassette is capable of being inserted into and removed from the receiving region when the lock member is in the open position, and the cassette is secured to the pump with the cassette base region within the receiving region and the delivery tube in operative engagement with the fluid drive component when the lock member is in the closed position. | 07-02-2015 |
20150182688 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER - Drug delivery reservoir cassette for a pump is provided. The cassette includes a cassette housing having a front surface, a back surface and lateral sidewalls, the cassette housing defining a transverse axis extending between the lateral sidewalls and a longitudinal axis perpendicular to the transverse axis. The cassette housing includes a cassette body region defining a fluid reservoir chamber therein, and a cassette base region having a boundary configured to be received by the pump, the boundary including a pair of opposing rails disposed on opposite sides of the longitudinal axis. The cassette base region can also include an engagement surface, alignment key, and/or support rib to align the cassette in a receiving region of the pump. A device for delivering a beneficial agent including a pump and cassette is also provided. | 07-02-2015 |
20150175694 | DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING - Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1α and IL-1β) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental. | 06-25-2015 |
20150175612 | CRYSTAL FORMS - The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (°2θ) of 6.0, 6.7, 10.4, 11.9, 17.5, 17.7, 21.5, 22.0, 22.7, and 24.2. | 06-25-2015 |
20150174194 | METHODS FOR TREATING LIVER TRANSPLANT RECIPIENTS - This application features interferon-free therapies for the prevention or treatment of HCV infection in liver transplant recipient. In one aspect, the treatment comprises administering a DAA combination to a liver transplant recipient after liver transplantation, wherein the DAA combination comprises Compound 1, ritonavir, Compound 2 and Compound 4. | 06-25-2015 |
20150139988 | GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS - Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions. | 05-21-2015 |
20150126545 | COMPOSITIONS CONTAINING KINASE INHIBITORS - A composition comprises a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea, in a mixture comprising (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. The composition is suitable for dilution with an IV solution for administration to a subject in need thereof for treatment of a cancer. | 05-07-2015 |
20150118229 | JAK1 SELECTIVE INHIBITOR AND USES THEREOF - The invention relates to the use of a JAK1 kinase-selective inhibitor that has minimal inhibitory activity towards Jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe Rheumatoid Arthritis) and/or bone loss, either alone or in combination with a DMARD (disease modifying anti-rheumatic drug), such as methotrexate. The invention also provides pharmaceutical composition, dosage formulation, administration route, and dosage schedule thereof. | 04-30-2015 |
20150087618 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 03-26-2015 |
20150073031 | ATRASENTAN MANDELATE SALTS - The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method. | 03-12-2015 |
20150065724 | DIASTEREOSELECTIVE METHODS FOR SYNTHESIZING COMPOUNDS - The present invention is directed to novel synthetic methods for preparing a compound of Structural Formula (I): | 03-05-2015 |
20150065508 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME - The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids. | 03-05-2015 |
20150056164 | Antiviral Compounds and Uses Thereof - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 02-26-2015 |
20150031884 | ANTI-VIRAL COMPOUNDS - The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. | 01-29-2015 |
20150031731 | POLYMORPH OF A PHARMACEUTICAL - A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed. | 01-29-2015 |
20150025024 | Solid Compositions - The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant. | 01-22-2015 |
20150025000 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. The therapies comprise administering 2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-exadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide (Compound I), or a pharmaceutically acceptable salt thereof, and another anti-HCV agent. Preferably, the therapies are both interferon- and ribavirin-free. The other anti-HCV agent can be a HCV polymerase inhibitor, an HCV NS5A inhibitor, an HCV entry inhibitor, a cyclophilin inhibitor, or an internal ribosome entry site inhibitor. Preferably, the other anti-HCV agent is an HCV polymerase inhibitor. Also preferably, the other anti-HCV agent is an HCV NS5A inhibitor. Also preferably, the other anti-HCV agent is administered concurrently with Compound I or a pharmaceutically acceptable salt thereof. In another example, the other anti-HCV agent is administered sequentially with Compound I or a pharmaceutically acceptable salt thereof. In still another embodiment, Compound I (or a pharmaceutically acceptable salt thereof) is co-administered with two or more other anti-HCV agents. For instance, Compound I (or a pharmaceutically acceptable salt thereof) can be co-administered with an HCV polymerase inhibitor and an HCV NS5A inhibitor. For another instance, Compound I (or a pharmaceutically acceptable salt thereof) can be co-administered with two different HCV polymerase inhibitors (e.g., one is a nucleoside polymerase inhibitor and the other is a non-nucleoside polymerase inhibitor; or both are nucleoside polymerase inhibitors; or both are non-nucleoside polymerase inhibitor). In yet another example, Compound I (or a pharmaceutically acceptable salt thereof) is co-administered with another HCV protease inhibitor and an HCV polymerase inhibitor. In still another example, Compound I (or a pharmaceutically acceptable salt thereof) is administered with two different HCV NS5A inhibitors. | 01-22-2015 |
20150024999 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 01-22-2015 |
20150023977 | PROTEIN FORMULATIONS AND METHODS OF MAKING SAME - The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality. | 01-22-2015 |
20150017168 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 01-15-2015 |
20150011602 | STABILIZED PHARMACEUTICAL DOSAGE FORMS COMPRISING ATRASENTAN - The present disclosure relates to: (a) stabilized pharmaceutical dosage forms comprising atrasenstan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent; (b) methods of using such pharmaceutical dosage forms to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods. | 01-08-2015 |
20140378666 | DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING - Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1α and IL-1β) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental. | 12-25-2014 |
20140378490 | Formulations of Phenyl Uracil Compounds - A pharmaceutical product comprising at least one phenyl uracil-based pharmaceutically active agent or an agent of related structural type and processes for obtaining such product. | 12-25-2014 |
20140377858 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 12-25-2014 |
20140377805 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 12-25-2014 |
20140371446 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS - The disclosure is directed to: (a) phosphacycle ligands; (b) methods of using such phosphacycle ligands in bond forming reactions; and (c) methods of preparing phosphacycle ligands. | 12-18-2014 |
20140364616 | ANTI-VIRAL COMPOUNDS - The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. | 12-11-2014 |
20140356909 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 12-04-2014 |
20140349970 | NOVEL TRICYCLIC COMPOUNDS - The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. | 11-27-2014 |
20140348856 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 11-27-2014 |
20140348838 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 11-27-2014 |
20140348834 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 11-27-2014 |
20140343267 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 11-20-2014 |
20140341913 | METHODS AND COMPOSITIONS FOR TREATING ASTHMA USING ANTI-IL-13 ANTIBODIES - The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof. | 11-20-2014 |
20140336167 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 11-13-2014 |
20140335564 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 11-13-2014 |
20140335014 | IL-1 ALPHA DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 11-13-2014 |
20140315883 | 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS - The invention provides a compound of Formula (I as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. | 10-23-2014 |
20140314745 | METHODS TO CONTROL PROTEIN HETEROGENEITY - The instant invention relates to the field of protein production and in particular to controlled protein heterogeneity compositions and processes for controlling the heterogeneity of proteins expressed in host cells. | 10-23-2014 |
20140308286 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 10-16-2014 |
20140294813 | TNF Binding Proteins - Provided are TNF binding proteins and methods of treatment using the same. Also provided are nucleic acids encoding the binding proteins and recombinant expression vectors and host cells for making such binding proteins. | 10-02-2014 |
20140286969 | ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS - The invention provides a stable formulation comprising an anti-EGFR antibody drug conjugate (ADC), including an anti-EGFR antibody, e.g., antibody 1, conjugated to an auristatin, e.g., MMAF, histidine, a sugar, and a surfactant. | 09-25-2014 |
20140275546 | AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES - A compound, (4s)-1-azaadamantane-4yl formate ester, is described. In addition, a process is described for preparing (4s)-1-azaadamantane-4yl formate ester, aminothiadiazole-phenyl phosphate salt, bromothiadizole-phenyl or (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1 | 09-18-2014 |
20140275540 | Processes For The Preparation Of An Apoptosis-Inducing Agent - Provided herein is a process for the preparation of an apoptosis-inducing agent, and chemical intermediates thereof. Also provided herein are novel chemical intermediates related to the process provided herein. | 09-18-2014 |
20140275494 | PROTEIN PURIFICATION USING DISPLACEMENT CHROMATOGRAPHY - Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein. | 09-18-2014 |
20140275011 | PYRIDINE CDK9 KINASE INHIBITORS - Disclosed are compound of Formula (Ia), | 09-18-2014 |
20140271633 | MAMMALIAN CELL CULTURE PERFORMANCE THROUGH SURFACTANT SUPPLEMENTATION OF FEED MEDIA - The present invention provides methods for increasing cell culture performance through the use of chemically defined feed media (CDFM). In particular, the present invention provides methods for the use of surfactants as supplements to CDFM to allow for higher concentrations of media components and thereby result in increased cell culture performance. | 09-18-2014 |
20140271632 | METHODS FOR MODULATING PROTEIN GLYCOSYLATION PROFILES OF RECOMBINANT PROTEIN THERAPEUTICS USING MONOSACCHARIDES AND OLIGOSACCHARIDES - The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells. | 09-18-2014 |
20140271458 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 09-18-2014 |
20140271457 | Dual Specific Binding Proteins Directed Against TNF - Engineered multivalent and multispecific binding proteins that bind TNFα and IL-13, TNFα and PGE2, or TNFα and NGF are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 09-18-2014 |
20140270897 | FLUID APPLICATORS FOR USE WITH TOPICAL MEDICATIONS - Fluid applicators for use with topical medications are disclosed herein. An example apparatus includes a housing and a fluid container disposed inside the housing. The example apparatus also includes a pump assembly disposed inside the housing and fluidly coupled to the fluid container. The example apparatus further includes an applicator coupled to the housing. The applicator defines an outlet and has a surface to be in contact with an application site on a person. The surface is in fluid communication with the pump assembly via the outlet. The example apparatus also includes an actuator operatively coupled to the pump assembly. Movement of the actuator from a first position to a second position is to operate the pump to dispense a dose of the fluid onto the surface. | 09-18-2014 |
20140255423 | ISOLATION AND PURIFICATION OF ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY - Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably Protein A affinity, ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention. | 09-11-2014 |
20140255410 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 09-11-2014 |
20140243340 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF - The present invention features compounds of formula I | 08-28-2014 |
20140243228 | HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES - System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity. | 08-28-2014 |
20140242077 | METHODS AND COMPOSITIONS FOR MODULATING AN IMMUNE RESPONSE - Provided are multispecific binding proteins and methods for using these multispecific binding proteins to modulate the activation state of immune cells, such as T-cells (e.g., cytotoxic T-cells). Also provided are methods of modulating an immune response (e.g., cell killing by cytotoxic T-cells) in a subject (e.g., a human subject). Also provided are nucleic acids, expression vectors and host cells encoding the multispecific binding proteins. | 08-28-2014 |
20140235638 | Anti-Infective Agents and Uses Thereof - This invention relates to: (a) compounds and salts thereof that, inter alia, HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 08-21-2014 |
20140235476 | MULTIVALENT BINDING PROTEIN COMPOSITIONS AND METHODS FOR IDENTIFYING VARIANTS OF SAME - Provided are protein, nucleic acid, and cellular libraries of multivalent binding proteins (e.g., DVD-Fab or DVD-Ig molecules) and the use of these libraries for the screening of multivalent binding proteins using cell surface display technology (e.g., yeast display). | 08-21-2014 |
20140234905 | CELL CULTURE IMPROVEMENTS - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 08-21-2014 |
20140234885 | METHODS FOR OPTIMIZING DOMAIN STABILITY OF BINDING PROTEINS - Provided are methods for measuring the inherent stability of intrachain disulphide-containing domains (e.g., antibody variable domains) and for optimizing the positioning of intrachain disulphide-containing domains within a protein (e.g., a multispecific binding protein, e.g., a DVD-Ig). Also provided are methods of making multispecific binding proteins (e.g., DVD-Ig molecules) comprising two or more antibody variable domains in which the antibody variable domains are optimally positioned within the multispecific binding proteins to enhance stability of the multispecific binding protein. Multispecific binding proteins optimized using the methods disclosed herein are also provided. | 08-21-2014 |
20140234208 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 08-21-2014 |
20140221622 | MONOVALENT BINDING PROTEINS - Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 08-07-2014 |
20140221621 | SINGLE-CHAIN MULTIVALENT BINDING PROTEIN COMPOSITIONS AND METHODS - Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display). | 08-07-2014 |
20140220020 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 08-07-2014 |
20140220019 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 08-07-2014 |
20140219913 | Dual Specific Binding Proteins Having a Receptor Sequence - Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 08-07-2014 |
20140219912 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 08-07-2014 |
20140213772 | CROSS-OVER DUAL VARIABLE DOMAIN IMMUNOGLOBULIN CONSTRUCTS - Engineered cross-over DVD-Ig binding proteins that bind to two or more target proteins (e.g., antigens) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 07-31-2014 |
20140213771 | MULTI-SPECIFIC BINDING PROTEINS - Engineered multi-specific binding proteins that bind to one or more target proteins (e.g., antigens) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 07-31-2014 |
20140213770 | HIGH-THROUGHPUT ANTIBODY HUMANIZATION - The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation. | 07-31-2014 |
20140213768 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 07-31-2014 |
20140213610 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS - Compounds of Formula (I) | 07-31-2014 |
20140213601 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 07-31-2014 |
20140213596 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT - Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 07-31-2014 |
20140213595 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 07-31-2014 |
20140212925 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 07-31-2014 |
20140212509 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE - Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed. | 07-31-2014 |
20140212423 | BLOOD-BRAIN BARRIER PENETRATING DUAL SPECIFIC BINDING PROTEINS - Engineered multivalent and multispecific binding proteins capable of penetrating the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 07-31-2014 |
20140212379 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 07-31-2014 |
20140207073 | Automatic Injection Device - Automatic injection device includes a housing, a syringe, a plunger, and a syringe carrier. The housing includes a barrel between a first end and a second end. The barrel includes an elongated window to allow viewing of contents inside the housing. The syringe is disposed within the housing and has a reservoir. The plunger is at least partially disposed within the syringe and includes a visual indicator. The syringe carrier is disposed within the housing and configured to contain the syringe and displace the syringe within the housing between a first position and a second position. The syringe carrier can be substantially transparent. The syringe carrier can have first and second legs and an extension disposed therebetween, and at least a portion of the extension can be configured to align with the window and the reservoir when the syringe carrier is in the first position. | 07-24-2014 |
20140206038 | CELL CULTURE IMPROVEMENTS - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 07-24-2014 |
20140205613 | ANTI-TNF AND ANTI-IL 17 COMBINATION THERAPY BIOMARKERS FOR INFLAMMATORY DISEASE - The invention provides methods for predicting the efficacy of anti-TNF and anti-IL17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level CXCL1 and/or CXCL5 markers in a sample derived from the subject. | 07-24-2014 |
20140205562 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 07-24-2014 |
20140199319 | METHODS FOR INCREASING THE EFFICIENCY OF HYBRIDOMA GENERATION - Disclosed herein are methods for improving the efficiency of the production of hybridomas, e.g., through enrichment of IgG expressing B cells. Also disclosed are hybridoma compositions produced using these methods as well as methods for producing antibodies with the hybridomas. | 07-17-2014 |
20140194418 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES - Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X | 07-10-2014 |
20140194349 | HIV Protease Inhibiting Compounds - A compound of the formula | 07-10-2014 |
20140187531 | APOPTOSIS PROMOTERS - Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member. | 07-03-2014 |
20140186377 | PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF - The present invention encompasses prostaglandin E | 07-03-2014 |
20140179676 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS - The invention provides a compound of Formula (I) | 06-26-2014 |
20140178389 | IL-1 BINDING PROTEINS - The disclosure provides binding proteins that specifically bind to IL-1α and IL-1β. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1α and/or IL-1β and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation. | 06-26-2014 |
20140178332 | IL-12/p40 BINDING PROTEINS - The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental. | 06-26-2014 |
20140171429 | BICYCLIC INHIBITORS OF ALK - The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, Formula (1) wherein R | 06-19-2014 |
20140171423 | AGENTS FOR TREATING PAIN AND USES THEREOF - This invention relates to: (a) compounds and salts thereof that, inter alia, treat pain; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 06-19-2014 |
20140162985 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS - The invention provides a compound of Formula (I) | 06-12-2014 |
20140161815 | CELL CULTURE METHODS TO REDUCE ACIDIC SPECIES - The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations. | 06-12-2014 |
20140161804 | BISPECIFIC IMMUNOBINDERS DIRECTED AGAINST TNF AND IL-17 - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 06-12-2014 |
20140155610 | PREPARATION OF PYRIDONECARBOXYLIC ACID ANTIBACTERIALS - A process for making
| 06-05-2014 |
20140155579 | DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING - Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1α and IL-β) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental. | 06-05-2014 |
20140155389 | BICYCLIC INHIBITORS OF ALK - The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R | 06-05-2014 |
20140155382 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 06-05-2014 |
20140155380 | Salt and Crystalline Forms Thereof of a Drug - A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed. | 06-05-2014 |
20140154256 | ANTI-IL1ALPHA/BETA DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 06-05-2014 |
20140148784 | WEARABLE AUTOMATIC INJECTION DEVICE FOR CONTROLLED ADMINISTRATION OF THERAPEUTIC AGENTS - Exemplary embodiments provide wearable automatic injection devices for administering a therapeutic agent to a patient's body at fast, controlled rates, for example, in a single fast bolus. Exemplary embodiments also provide methods for assembling wearable automatic injection devices for administering a therapeutic agent to a patient at fast, controlled rates. Exemplary embodiments also provide methods for using wearable automatic injection devices for administering a therapeutic agent to a patient at fast, controlled rates. | 05-29-2014 |
20140148573 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 05-29-2014 |
20140134675 | CELL CULTURE IMPROVEMENTS - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 05-15-2014 |
20140134674 | CELL CULTURE IMPROVEMENTS - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 05-15-2014 |
20140134172 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 05-15-2014 |
20140134171 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 05-15-2014 |
20140128840 | Shroud Deployment in Automatic Injection Devices - Exemplary embodiments provide automatic injection devices in which a shroud is automatically deployed to protectively sheath a needle after an injection is performed. Exemplary embodiments also provide shroud deployment assemblies including a shroud and a syringe carrier that, when cooperatively configured in an automatic injection device, ensure that the shroud is automatically and completely deployed after an injection is performed using the automatic injection device. Exemplary embodiments are also configured to ensure that, once the shroud is deployed to an extended position to sheath the needle, accidental forces applied to the shroud do not succeed in subsequently retracting the shroud to a retracted position in which the needle would become exposed. | 05-08-2014 |
20140113910 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 04-24-2014 |
20140107119 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein. | 04-17-2014 |
20140107017 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 04-17-2014 |
20140100359 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 04-10-2014 |
20140100162 | PREVENTION OF KIDNEY INJURY DISEASE - The present invention relates to a dosage regime of a peptide analogues of [alpha]-melanocyte-stimulating hormone ([alpha]-MSH), which possesses an increased efficacy compared to the native [alpha]-MSH peptide in the treatment or prevention of kidney injury or disease. | 04-10-2014 |
20140099671 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 04-10-2014 |
20140099313 | INTERLEUKIN-13 BINDING PROTEINS - The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental. | 04-10-2014 |
20140094471 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 04-03-2014 |
20140093521 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 04-03-2014 |
20140088106 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 03-27-2014 |
20140080886 | Methods for Treating HCV - Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection. | 03-20-2014 |
20140080869 | Methods for Treating HCV - Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection. | 03-20-2014 |
20140080868 | Methods for Treating HCV - Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection. | 03-20-2014 |
20140080803 | NOVEL TRPV3 MODULATORS - Disclosed herein are modulators of TRPV3 of Formula (I) | 03-20-2014 |
20140072585 | NOVEL PURIFICATION OF ANTIBODIES USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY - Disclosed herein are compositions and methods for purifying antibody products from a sample matrix. In particular, the present invention relates to compositions and methods for purifying antibody products employing hydrophobic interaction chromatography media. In certain embodiments, the invention provides a method for reducing process-related impurities (e.g., host cell proteins), as well as product-related substances, including molecular weight variants (e.g., aggregates and fragments of the antibody product). | 03-13-2014 |
20140066621 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 03-06-2014 |
20140057890 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein. | 02-27-2014 |
20140057889 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein. | 02-27-2014 |
20140057835 | METHODS FOR TREATING HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 02-27-2014 |
20140051683 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS - Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed. | 02-20-2014 |
20140038919 | HEPATITIS C INHIBITORS AND USES THEREOF - This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 02-06-2014 |
20140024838 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 - 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed. | 01-23-2014 |
20140024579 | METHODS FOR TREATING HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 01-23-2014 |
20140017256 | CRYSTALLINE ANTI-HUMAN IL-12 ANTIBODIES - The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions. | 01-16-2014 |
20140017246 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 01-16-2014 |
20140004531 | Secretory Protein Biomarkers For High Efficiency Protein Expression | 01-02-2014 |
20130344144 | LOW FLUSH NIACIN FORMULATION - The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment. | 12-26-2013 |
20130344084 | CELL CULTURE METHODS TO REDUCE ACIDIC SPECIES - The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations. | 12-26-2013 |
20130343993 | RADIOLABELED 5-HT6 LIGANDS - Compounds of formula (I) are disclosed | 12-26-2013 |
20130343992 | RADIOLABELED PDE10A LIGANDS - Compounds of formula (I) are disclosed | 12-26-2013 |
20130338344 | PROTEIN PURIFICATION METHODS TO REDUCE ACIDIC SPECIES - The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification. | 12-19-2013 |
20130338169 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME - The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids. | 12-19-2013 |
20130336957 | NOVEL PURIFICATION OF HUMAN, HUMANIZED, OR CHIMERIC ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY - Disclosed herein are compositions and methods for the isolation and purification of antibodies from a sample matrix. In particular, the present invention relates to compositions and methods for isolating and purifying antibodies exhibiting low or high binding capacity for Protein A resin. In certain embodiments, the methods herein employ a kosmotropic salt solution, an affinity chromatographic step, and may include one or more additional chromatography and/or filtration steps to achieve the desired degree of purification. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein. | 12-19-2013 |
20130330359 | COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS - Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders. | 12-12-2013 |
20130330347 | COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITE DEGENERATION - Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders. | 12-12-2013 |
20130330343 | COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS - Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders. | 12-12-2013 |
20130317056 | NEURONAL NICOTINIC AGONISTS AND METHODS OF CORRELATING COMT SNPS - This application is directed to a-neuronal nicotinic receptor agonists selective for α7-subtype that are useful for improving cognition impairment in patients having schizophrenia, a schizophreniform disorder or a related schizophrenia spectrum psychotic disorder. Compounds and compositions containing such compounds, and methods of using such compound and compositions are described herein. | 11-28-2013 |
20130317055 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE - An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof. | 11-28-2013 |
20130317054 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE - An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, or a pharmaceutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof. | 11-28-2013 |
20130310625 | VELIPARIB IN COMBINATION WITH WHOLE BRAIN RADIATION THERAPY FOR THE TREATMENT OF BRAIN METASTASES - The invention relates to a method for the treatment of brain metastases from non-small cell lung cancer in a subject, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of whole brain radiation. | 11-21-2013 |
20130310378 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS - The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R | 11-21-2013 |
20130303511 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 11-14-2013 |
20130303510 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 11-14-2013 |
20130303509 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 11-14-2013 |
20130303508 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 11-14-2013 |
20130280274 | METHODS TO MODULATE LYSINE VARIANT DISTRIBUTION - The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the distribution or amount of lysine variants expressed by host cells, as well as to compositions and processes for controlling the amount of lysine variants present in purified preparations. | 10-24-2013 |
20130280267 | PURIFIED ANTIBODY COMPOSITION - The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. | 10-24-2013 |
20130273059 | PURIFIED ANTIBODY COMPOSITION - The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. | 10-17-2013 |
20130266573 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 10-10-2013 |
20130261129 | CHEMOKINE RECEPTOR ANTAGONISTS - Disclosed herein are chemokine receptor antagonists of formula (I) | 10-03-2013 |
20130252891 | Therapeutically Active Alpha-MSH Analogues - The invention describes peptide analogues of α-melanocyte-stimulating hormone (α-MSH), which possess an increased efficacy compared to the native α-MSH peptide. The α-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to α-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions. | 09-26-2013 |
20130245038 | Method For Selecting Or Identifying A Subject For V1B Antagonist Therapy - Provided herein is a method for detecting an HPA axis function marker in a biological sample. The method may be used to determine whether a patient is a suitable candidate for treatment with a V | 09-19-2013 |
20130236872 | Automatic Injection Training Device - Exemplary embodiments of the present disclosure provide reusable training automatic injection training devices, and components thereof, to simulate and/or mimic an operation of an actual automatic injection device. Exemplary embodiments of the training device can provide audible instructions, which can be in different languages, output from circuitry associated with the training device. Exemplary embodiment of the training device can be a self-contained and portable device that mimics a shape, size, and function of an actual automatic injection device without including a needle or any drug on board. Exemplary embodiments can be implemented to train a user on an operation and/or usage of an actual automatic injection device using embodiments of the automatic injection training devices so that a user can practice an autoinjection without injecting a therapeutic agent, such as a liquid drug, into a recipient | 09-12-2013 |
20130236458 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-13 AND/OR IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 09-12-2013 |
20130225647 | COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents. | 08-29-2013 |
20130225589 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 08-29-2013 |
20130224149 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS - This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such compositions. | 08-29-2013 |
20130217876 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS - The disclosure is directed to: (a) phosphacycle ligands; (b) catalyst compositions comprising phosphacycle ligands; and (c) methods of using such phosphacycle ligands and catalyst compositions in bond forming reactions. | 08-22-2013 |
20130217628 | Therapeutically Active Alpha-MSH Analogues - The invention describes peptide analogues of α-melanocyte-stimulating hormone (α-MSH), which posses an increased efficacy compared to the native α-MSH peptide. The α-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to α-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions. | 08-22-2013 |
20130210880 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY - The present invention relates to isoindoline derivatives of the formula (I) | 08-15-2013 |
20130210827 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS - The present application relates to calcium channel inhibitors comprising compounds of formula (I), formula (II), formula (III), or formula (IV), | 08-15-2013 |
20130203749 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy - The present invention relates to tetrahydroisoquinoline of the formula (I) | 08-08-2013 |
20130199313 | METHOD FOR EVALUATING THE SOLUBILITY OF A CRYSTALLINE SUBSTANCE IN A POLYMER - A method for evaluating the solubility of a crystalline substance in a polymer comprises a) providing at least one sample of an intimate crystalline substance/polymer mixture at a predetermined crystalline substance concentration; b) annealing the sample at a constant temperature T | 08-08-2013 |
20130195871 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins that bind two different (e.g., nonoverlapping) epitopes of the same receptor or two different receptors expressed on the same cell are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 08-01-2013 |
20130195754 | IL-l BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 08-01-2013 |